Oliver Keown, MD

CEO & Founder at Oath Surgical

📍 United States🔄 Updated September 2026💼 8 investments📅 6 years investing🗓 Last invested May 2023
VC🌍 United States
8
Total investments
0
Early stage
2
Mid stage
3
Late stage
6y
Years active

Portfolio

8 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Investor & Board Observer
May 2023
At Capstan Medical, we’re driven by an unwavering commitment to transforming the treatment of structural heart disease. By merging surgical robotics with catheter-based technology and next generation implants, we’ve pioneered a patient-optimized approach to repair and replace heart valves.
Investor & Board Observer
Oct 2022
Medcrypt provides data security as a service to medical device OEMs. From medical imaging devices to pacemakers, Medcrypt ensures that devices act only on instructions from trusted sources.
Investor & Board Observer
Sep 2022
Neocis is transforming dental implant surgery with advanced robotics. Manufacturer of Yomi, the first and only FDA-cleared robotic device for dental surgery, Neocis works closely with leading surgeons to better understand their needs and treatment challenges. The company is committed to developing innovative technologies and approaches that help advance patient care and improve quality of life.
Investor & Board Observer
Aug 2022
Optellum was founded so that every lung cancer patient is treated at the earliest possible stage, and cured. We are redefining early interception of lung disease, by enabling every clinician, in every hospital, to manage their patients in the optimal way. Our first product is the first Clinical Decision Support software for personalized early diagnosis & treatment of lung cancer, based on Artificial Intelligence & Machine Learning applied to the world’s largest clinical dataset. We are a team of world-leading medical imaging software, AI, and clinical experts who met at Oxford’s world-renowned computer vision laboratory. Between us, we have track records of bringing innovation to market through over 10 start-up companies, resulting already in 5 trade-sales and one IPO. We are backed by an Advisory Board comprising world-leading clinicians (global authors of medical guidelines) and experts in deep learning. We are building up our development team – join our fight against cancer, working together with former software engineers from top technology companies (Amazon, Facebook, Redhat) and veterans of medical imaging startups. Learn more at http://www.optellum.com/.
Investor & Board Observer
Nov 2021
Flywheel is pioneering the future of medical imaging data management and analysis. We enable a world where every healthcare decision is informed, precise, impactful and leverages the power of trustworthy AI. The Flywheel platform empowers healthcare professionals, researchers, and innovators to access and curate medical imaging data for the development of cutting-edge imaging algorithms that accelerate biomarker discovery and deliver advances in patient outcomes.
Investor & Board Observer
Apr 2021
Endogenex is a clinical stage company focused on improving outcomes and quality of life for patients living with Type 2 Diabetes (T2D). Endogenex has developed a novel therapy that utilizes pulsed electric fields to promote regeneration of the duodenal mucosa for improvement in glycemic control in patients with T2D.
Investor & Board Observer
Dec 2020
SURGE seeks to dramatically improve cancer patient survival by disrupting how, when, and where cancer immunotherapy is deployed -- focusing 100% of the effective dose at the right place and at the right time. Surgery is the standard of care for most patients with solid tumors, and we are working tirelessly to ensure that nobody grieves the loss of a loved one to preventable post-surgical cancer recurrence.
Investor & Board Observer
Jul 2020
The KelaHealth AI-Enabled Surgical Intelligence Platform delivers patient-specific predictive insights, risk stratification, and recommended interventions at key decision points to improve clinical quality and clinical operations. We work with leading health systems and MedTech companies to improve clinical and financial outcomes across the entire surgical journey. Working together, we are creating a data-driven "AI Ecosystem" to optimize surgical care.
Experience · 12 entries
All (12)
Investments (8)
Founder (3)
Board (8)
2023
Founder & CEO
Nov 2023
Were building the future of surgical care—one that’s surgeon-led, tech-powered, and value-based by design. In creating and deploying the first vertically integrated surgical care system - combining AI and technology with operationally excellent surgical centers - Oath Surgical delivers high quality care that’s better, faster, and more affordable for patients, providers, and payors. Oath Surgical offers a rare proof point for how value-based care can work and scale in the real world.
Investor & Board Observer
May 2023
At Capstan Medical, we’re driven by an unwavering commitment to transforming the treatment of structural heart disease. By merging surgical robotics with catheter-based technology and next generation implants, we’ve pioneered a patient-optimized approach to repair and replace heart valves.
2022
Investor & Board Observer
Oct 2022
Medcrypt provides data security as a service to medical device OEMs. From medical imaging devices to pacemakers, Medcrypt ensures that devices act only on instructions from trusted sources.
Investor & Board Observer
Sep 2022
Neocis is transforming dental implant surgery with advanced robotics. Manufacturer of Yomi, the first and only FDA-cleared robotic device for dental surgery, Neocis works closely with leading surgeons to better understand their needs and treatment challenges. The company is committed to developing innovative technologies and approaches that help advance patient care and improve quality of life.
Investor & Board Observer
Aug 2022
Optellum was founded so that every lung cancer patient is treated at the earliest possible stage, and cured. We are redefining early interception of lung disease, by enabling every clinician, in every hospital, to manage their patients in the optimal way. Our first product is the first Clinical Decision Support software for personalized early diagnosis & treatment of lung cancer, based on Artificial Intelligence & Machine Learning applied to the world’s largest clinical dataset. We are a team of world-leading medical imaging software, AI, and clinical experts who met at Oxford’s world-renowned computer vision laboratory. Between us, we have track records of bringing innovation to market through over 10 start-up companies, resulting already in 5 trade-sales and one IPO. We are backed by an Advisory Board comprising world-leading clinicians (global authors of medical guidelines) and experts in deep learning. We are building up our development team – join our fight against cancer, working together with former software engineers from top technology companies (Amazon, Facebook, Redhat) and veterans of medical imaging startups. Learn more at http://www.optellum.com/.
Show all 12 entries ↓
Investment activity
2020–2023 · 8 investments
20202202122022320231
Recent (last 2 years)Earlier